Corcept Therapeutics Profit Margin

Corcept Therapeutics (CORT) currently reports a profit margin of 6.57% as of June 2026. That compares with 18.5% in the prior-year period — down 64.5% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Corcept Therapeutics's profit margin history and peer comparisons.

Corcept Therapeutics's profit margin decreased from 18.5% to 6.57% — a 64.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Corcept Therapeutics's profit margin of 6.57% is lower than the Healthcare sector average of 21.34%. That is roughly 69.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Corcept Therapeutics's current 6.57% should be judged against Healthcare norms (sector average: 21.34%) and against CORT's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 6.57%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Corcept Therapeutics, and consider following CORT for alerts when major investors trade the stock.